Markers for Sub-Clinical Cardiovascular Risk Assessment (EU-MASCARA)

consortiapedia.fastercures.org/consortia/eumascara/

Research Areas

- Tool Development
- Biomarker Research
  - Diagnostic, Genomic Biomarker

At a Glance

- Status: Active Consortium
- Year Launched: 2011
- Initiating Organization: European Commission Seventh Framework Programme (FP7)
- Initiator Type: Government
- Location: Europe

Abstract

The Markers for Sub-Clinical Cardiovascular Risk Assessment (EU-MASCARA) consortium aims to improve diagnosis of cardiovascular diseases and prediction of cardiovascular risk by analyzing a panel of biomarkers. EU-MASCARA aims to validate biomarkers that have been proposed to be associated with cardiovascular disease and risk across different disease entities and also in independent general population samples. The most robust biomarkers will be implemented in novel biochip-based assays for clinical use.

Mission

The Markers for Sub-Clinical Cardiovascular Risk Assessment (EU-MASCARA) consortium aims to examine genetic, proteomic, and metabolomic markers together with markers of inflammation, oxidative stress, and cardiac remodeling to study their incremental diagnostic and predictive value over and above existing diagnostic and predictive algorithms. For this purpose, a large number of cohorts from different European regions, both patient and population cohorts that have been accurately
assessed for cardiovascular phenotypes, are readily available to the consortium. Access to clinical samples and to standardized cardiovascular phenotypes will be granted by a strong clinical platform as one of the key work packages of EU-MASCARA. Both cross-sectional and prospective analyses will be performed in hopes of developing improved risk prediction scores.

Consortium History

Start date: Dec. 1, 2011
End date: Nov. 30, 2015

Structure & Governance

The consortium is heavily supported by contributions of SMEs in key areas of the proposed research: biomarker testing, data handling and analysis, assay development, and project management. EU-MASCARA is further characterized by a strong integrative approach both within and across work packages, with results from one task informing strategies of research in other tasks. With a dedicated bioinformatics and health economic platform, the most robust biomarkers will be selected and analyzed for their benefit in clinical practice.

Financing

Funded by EU FP7.

Over 80 peer-reviewed published papers, most recently “Heritability and other determinants of left ventricular diastolic function in the family-based population study.”

Homepage

http://www.eu-mascara.eu/

Points of Contact

Kite Innovation (Europe) Ltd
Sponsors & Partners

University of Glasgow  
Emergentec Biodevelopment GmbH  
Kite Innovation (Europe) Limited  
la Fundacion para la investigacion del Hospital Clinico de la Comunidad Valenciana  
ACS Biomarker BV  
Istituto Auxologico Italiano  
Randox Clinics Limited  
Maastricht University  
Fundacion Para la Investigacion Medica Aplicada FIMA  
Mosaiques Diagnostics GmbH  
Medizinische Universitat Graz  
Medizinische Hochschule Hannover  
Universita degli Studi di Milano – Bicocca  
Katholieke Universiteit Leuven  
Charite – Universitatsmedizin Berlin

Updated: 04/22/2016